Tether, a prominent stablecoin provider, used $200 million to acquire a controlling interest in Blackrock Neurotech, a developer of brain-computer interfaces, through its venture capital division, Tether Evo.

Blackrock Neurotech produces medical devices powered by brain signaling to aid individuals with neurological disorders and paralysis. It is important to note that the tech company is not affiliated with the large asset management firm BlackRock.

The goal of Tether in investing in Blackrock Neurotech is to support the promotion and implementation of medical solutions that have benefited more than 40 patients. Furthermore, Blackrock Neurotech aims to use the funding to continue being a significant player in the BCI field with a focus on human advancement in the long term.

Blackrock Neurotech is committed to helping millions worldwide who are affected by neurological disorders, paralysis, and other conditions that impact their ability to function.

Tether, the company behind USDT, which is the largest stablecoin with a market capitalization of $110 billion, has established four divisions to expand beyond the stablecoin market.

Paolo Ardoino, CEO of Tether, emphasized Tether's support for transformative technologies, highlighting the potential of Blackrock Neurotech's Brain-Computer-Interfaces to revolutionize communication, rehabilitation, and cognitive enhancement. He expressed Tether's excitement to embark on this journey with Blackrock Neurotech.

Co-founder Florian Solzbacher of Blackrock Neurotech stressed the company's dedication to assisting individuals in regaining their functions, noting that this is a long-term endeavor that requires committed and innovative partners.